Global Incretin-Based Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Incretin-Based Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Incretin-Based Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Incretin-Based Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oral Drugs and Injectable Drugs are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Incretin-Based Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Incretin-Based Drugs key manufacturers include GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company and Sanofi, etc. GlaxoSmithKline, Johnson & Johnson, Merck & Co are top 3 players and held % sales share in total in 2022.
Incretin-Based Drugs can be divided into Glucagon-like peptide-1 receptor (GLP-1) agonists and Dipeptidyl Peptidase-4 (DPP-4) inhibitors, etc. Glucagon-like peptide-1 receptor (GLP-1) agonists is the mainstream product in the market, accounting for % sales share globally in 2022.
Incretin-Based Drugs is widely used in various fields, such as Oral Drugs and Injectable Drugs, etc. Oral Drugs provides greatest supports to the Incretin-Based Drugs industry development. In 2022, global % sales of Incretin-Based Drugs went into Oral Drugs filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Incretin-Based Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report

GlaxoSmithKline
Johnson & Johnson
Merck & Co
AstraZeneca
Novartis
Eli Lilly and Company
Boehringer Ingelheim
Takeda Pharmaceutical Company
Sanofi
Segment by Type
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Oral Drugs
Injectable Drugs
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Incretin-Based Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Incretin-Based Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Incretin-Based Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Incretin-Based Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Incretin-Based Drugs introduction, etc. Incretin-Based Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Incretin-Based Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Incretin-Based Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Incretin-Based Drugs key manufacturers include GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company and Sanofi, etc. GlaxoSmithKline, Johnson & Johnson, Merck & Co are top 3 players and held % sales share in total in 2022.
Incretin-Based Drugs can be divided into Glucagon-like peptide-1 receptor (GLP-1) agonists and Dipeptidyl Peptidase-4 (DPP-4) inhibitors, etc. Glucagon-like peptide-1 receptor (GLP-1) agonists is the mainstream product in the market, accounting for % sales share globally in 2022.
Incretin-Based Drugs is widely used in various fields, such as Oral Drugs and Injectable Drugs, etc. Oral Drugs provides greatest supports to the Incretin-Based Drugs industry development. In 2022, global % sales of Incretin-Based Drugs went into Oral Drugs filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Incretin-Based Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report

By Company
GlaxoSmithKline
Johnson & Johnson
Merck & Co
AstraZeneca
Novartis
Eli Lilly and Company
Boehringer Ingelheim
Takeda Pharmaceutical Company
Sanofi
Segment by Type
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Segment by Application
Oral Drugs
Injectable Drugs
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Incretin-Based Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Incretin-Based Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Incretin-Based Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Incretin-Based Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Incretin-Based Drugs introduction, etc. Incretin-Based Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Incretin-Based Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
